Early Change in Fecal Calprotectin Predicts One-Year O Diagnosed With Ulcerative Colitis

Journal of Pediatric Gastroenterology and Nutrition

74, 72

DOI: 10.1097/mpg.0000000000003291

Citation Report

#	Article	IF	Citations
1	Vedolizumab as the First-Line of Biologicals for Pediatric Patients With Ulcerative Colitis. Clinical Therapeutics, 2022, 44, 1028-1032.	3.4	7
2	Validation of Predictive Models for Disease Outcomes in Paediatric Ulcerative Colitis: A Multicentre Prospective Inception Cohort. Alimentary Pharmacology and Therapeutics, 2023, 58, 182-190.	7.7	16
3	Editorial: Predicting Paediatric Ulcerative Colitis Outcomes—How Can We Improve?. Alimentary Pharmacology and Therapeutics, 2023, 58, 258-259.	7.7	1
4	Transcutaneous Auricular Vagus Nerve Stimulation Attenuates Inflammatory Bowel Disease in Children: A Proof-of-Concept Clinical Trial. Bioelectronic Medicine, 2023, 9, 1-13.	8.1	53
5	Change of Fecal Calprotectin Is a Good Biomarker of Clinical Outcomes in Pediatric Patients With Ulcerative Colitis. Journal of Pediatric Gastroenterology and Nutrition, 2024, 78, 747-747.	3.3	0
6	Predicting Complications in Paediatric Ulcerative Colitis: A Longitudinal Multicentre Cohort Study. Alimentary Pharmacology and Therapeutics, 2024, 60, 1421-1434.	7.7	7
7	Value of Single-Center Fecal Calprotectin in the Early Diagnosis and Assessment of Necrotizing Enterocolitis in Premature Infants. Frontiers in Pediatrics, 2025, 13, 1598448.	2.4	4
8	Combining Mucosal Microbiome and Host Multi-Omics Data Shows Prognostic Potential in Paediatric Ulcerative Colitis. Nature Communications, 2025, 16, 7157.	18.1	17
9	Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care—An Updated Evidence-Based Consensus Guideline From the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation. Journal of Pediatric Gastroenterology and Nutrition, 2025, 81, 765-815.	3.3	47
10	Updated Treatment Targets in Inflammatory Bowel Disease (STRIDE-III): An Initiative of the International Organization for the Study of IBD. The Lancet Gastroenterology and Hepatology, 2026, .	29.4	0